Efavirenz in Treating Patients With Metastatic Prostate Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut Bergonié
• Treatments: Efavirenz

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed prostate cancer

• Metastatic disease

• Castration-refractory disease

• No clinical symptoms related to disease progression

PATIENT CHARACTERISTICS:

• WHO performance status 0-2

PRIOR CONCURRENT THERAPY:

• Not specified